Drug intelligence / Profile preview

MED102

Development stage: Preclinical
Lead developer: Medley Therapeutics
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

MED102 is an investigational RNA-based therapy being developed by Medley Therapeutics for the treatment of cardiac arrhythmias. Currently in the preclinical and IND-enabling stages, the drug utilizes an undisclosed RNA-based mechanism to address heart rhythm disorders. It is part of the company's regenerative medicine pipeline, which aims to leverage RNA technology to modulate biological pathways for cardiovascular conditions. While the specific molecular target has not been publicly disclosed, the program represents a novel approach to treating arrhythmias through RNA modulation.

Beyond the preview

Go deeper on MED102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MED102.

Explore the full profile